DIFFERENTIAL DIAGNOSIS OF PAROXYSMAL STATES: LITERATURE REVIEW AND ANALYSIS OF A CLINICAL CASE ON THE EXAMPLEOF CLOCCS-SYNDROME IN A YOUNG MAN.

Diagnosis of paroxysmal conditions in neurology is one of the most difficult problems. Particular difficulties are caused by differential diagnosis of epileptic and non-epileptic paroxysmal states. There are no absolutely pathognomonic signs of epileptic and non-epileptic seizures.

The peculiarities of the heart rate variability and electroencephalogram changes in patients with epilepsy and cardiovascular pathology.

Objective: Introduction: Epidemiological studies have shown that the risk of myocardial infarction and stroke is significantly higher in patients with epilepsy compared with people not suffering from epilepsy. The aim of the study was to study the parameters of HRV and EEG in patients with epilepsy to identify risk factors for cardiovascular pathology.

Patients And Methods: Materials and methods: We observed 50 patients with epilepsy without cardiovascular pathology (group 1) and 56 patients with epilepsy and cardiovascular pathology (group 2).

Dynamics of epidemiological indications of epilepsy prevalence, morbidity and disability among children in kharkiv region, Ukraine.

Objective: Introduction: According to the World Health Organization, epilepsy is one of the most common diseases of the central nervous system, which affects 0.5 to 2% of the entire population The aim is comparison of prevalence, incidence and disability from nervous diseases and epilepsy among children of the Kharkiv region of Ukraine and the results are compared with global figures.

Patients And Methods: Materials and methods: Epidemiological indicators, namely the prevalence and incidence.

Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial.

Purpose: Double-blind randomized trial to assess efficacy and tolerability of once-daily extended-release levetiracetam (LEV XR) tablets (2 x 500 mg) as add-on therapy in patients (12-70 years old) with partial-onset seizures (POS) refractory to one to three antiepileptic drugs.

Methods: After an 8-week prospective baseline-period, eligible patients were randomized (1:1) to once-daily LEV XR 1,000 mg/day or placebo for 12 weeks. Evaluations included changes from baseline in POS-frequency/week, responders (>or=50% reduction in POS-frequency/week), seizure-freedom, adverse events, laboratory tests, physical and neurologic examinations, vital signs, body-weight, and 12-lead electrocardiogram.